Year |
Citation |
Score |
2023 |
Zhou Y, Jadlowsky J, Baiduc C, Klattenhoff AW, Chen Z, Bennett AD, Pumphrey NJ, Jakobsen BK, Riley JL. Chimeric antigen receptors enable superior control of HIV replication by rapidly killing infected cells. Plos Pathogens. 19: e1011853. PMID 38100526 DOI: 10.1371/journal.ppat.1011853 |
0.498 |
|
2023 |
Jung IY, Noguera-Ortega E, Bartoszek R, Collins SM, Williams E, Davis M, Jadlowsky JK, Plesa G, Siegel DL, Chew A, Levine BL, Berger SL, Moon EK, Albelda SM, Fraietta JA. Tissue-resident memory CAR T cells with stem-like characteristics display enhanced efficacy against solid and liquid tumors. Cell Reports. Medicine. 101053. PMID 37224816 DOI: 10.1016/j.xcrm.2023.101053 |
0.349 |
|
2022 |
Jung IY, Narayan V, McDonald S, Rech AJ, Bartoszek R, Hong G, Davis MM, Xu J, Boesteanu AC, Barber-Rotenberg JS, Plesa G, Lacey SF, Jadlowsky JK, Siegel DL, Hammill DM, et al. BLIMP1 and NR4A3 transcription factors reciprocally regulate antitumor CAR T cell stemness and exhaustion. Science Translational Medicine. 14: eabn7336. PMID 36350986 DOI: 10.1126/scitranslmed.abn7336 |
0.459 |
|
2021 |
Kong W, Dimitri A, Wang W, Jung IY, Ott CJ, Fasolino M, Wang Y, Kulikovskaya I, Gupta M, Yoder T, DeNizio JE, Everett JK, Williams EF, Xu J, Scholler J, ... ... Jadlowsky JK, et al. BET bromodomain protein inhibition reverses chimeric antigen receptor extinction and reinvigorates exhausted T cells in chronic lymphocytic leukemia. The Journal of Clinical Investigation. 131. PMID 34396987 DOI: 10.1172/JCI145459 |
0.433 |
|
2021 |
Zhou Y, Maldini CR, Jadlowsky J, Riley JL. Challenges and Opportunities of Using Adoptive T-Cell Therapy as Part of an HIV Cure Strategy. The Journal of Infectious Diseases. 223: 38-45. PMID 33586770 DOI: 10.1093/infdis/jiaa223 |
0.491 |
|
2021 |
Tebas P, Jadlowsky JK, Shaw PA, Tian L, Esparza E, Brennan A, Kim S, Naing SY, Richardson MW, Vogel AN, Maldini CR, Kong H, Liu X, Lacey SF, Bauer AM, et al. CCR5-edited CD4 T cells augment HIV-specific immunity to enable post rebound control of HIV replication. The Journal of Clinical Investigation. PMID 33571163 DOI: 10.1172/JCI144486 |
0.492 |
|
2020 |
Jacobson JM, Jadlowsky JK, Lacey SF, Fraietta JA, Plesa G, Chono H, Lee DH, Kulikovskaya I, Bartoszek C, Chen F, Dimitri A, Levine BL, Veloso EA, Hwang WT, June CH. Autologous CD4 T Lymphocytes Modified with a Tat-Dependent, Virus-Specific Endoribonuclease Gene in HIV-Infected Individuals. Molecular Therapy : the Journal of the American Society of Gene Therapy. PMID 33186691 DOI: 10.1016/j.ymthe.2020.11.007 |
0.464 |
|
2020 |
Lundh S, Jung IY, Dimitri A, Vora A, Melenhorst JJ, Jadlowsky JK, Fraietta JA. Clinical practice: chimeric antigen receptor (CAR) T cells: a major breakthrough in the battle against cancer. Clinical and Experimental Medicine. PMID 32333215 DOI: 10.1007/S10238-020-00628-1 |
0.469 |
|
2020 |
Stadtmauer EA, Fraietta JA, Davis MM, Cohen AD, Weber KL, Lancaster E, Mangan PA, Kulikovskaya I, Gupta M, Chen F, Tian L, Gonzalez VE, Xu J, Jung IY, Melenhorst JJ, ... ... Jadlowsky JK, et al. CRISPR-engineered T cells in patients with refractory cancer. Science (New York, N.Y.). PMID 32029687 DOI: 10.1126/Science.Aba7365 |
0.439 |
|
2020 |
Xu J, Gohil M, Stadtmauer E, Fraietta J, Gonzalez V, Salas-McKee J, Jadlowsky J, Gladney W, Lamontagne A, Fesnak A, Siegel D, Levine B, Lacey S, June C, Davis M. Characterization of autologous T cells engineered to express NY-ESO-1 TCR with multiplexed CRISPR/Cas9 editing (NYCE T Cells) Cytotherapy. 22: S35-S36. DOI: 10.1016/J.Jcyt.2020.03.027 |
0.482 |
|
2020 |
Gladney W, Hexner E, Salas-McKee J, Fesnak A, Jadlowsky J, Plesa G, Leskowitz R, Chew A, Dai A, Gohil M, Xu J, Siegel D, Lacey S, Davis M, June C. Pre-clinical development of multiplex-CRISPR-edited cell and gene therapy products Cytotherapy. 22: S35. DOI: 10.1016/J.Jcyt.2020.03.026 |
0.466 |
|
2019 |
Salas-Mckee J, Kong W, Gladney WL, Jadlowsky JK, Plesa G, Davis MM, Fraietta JA. CRISPR/Cas9-based genome editing in the Era of CAR T cell immunotherapy. Human Vaccines & Immunotherapeutics. PMID 30735463 DOI: 10.1080/21645515.2019.1571893 |
0.462 |
|
2017 |
Marcucci KT, Jadlowsky JK, Hwang WT, Suhoski-Davis M, Gonzalez VE, Kulikovskaya I, Gupta M, Lacey SF, Plesa G, Chew A, Melenhorst JJ, Levine BL, June CH. Retroviral and Lentiviral Safety Analysis of Gene-Modified T Cell Products and Infused HIV and Oncology Patients. Molecular Therapy : the Journal of the American Society of Gene Therapy. PMID 29203150 DOI: 10.1016/J.Ymthe.2017.10.012 |
0.458 |
|
2014 |
Jadlowsky JK, Wong JY, Graham AC, Dobrowolski C, Devor RL, Adams MD, Fujinaga K, Karn J. Negative elongation factor is required for the maintenance of proviral latency but does not induce promoter-proximal pausing of RNA polymerase II on the HIV long terminal repeat. Molecular and Cellular Biology. 34: 1911-28. PMID 24636995 DOI: 10.1128/Mcb.01013-13 |
0.455 |
|
2012 |
Richardson MW, Jadlowsky J, Didigu CA, Doms RW, Riley JL. Kruppel-like factor 2 modulates CCR5 expression and susceptibility to HIV-1 infection. Journal of Immunology (Baltimore, Md. : 1950). 189: 3815-21. PMID 22988032 DOI: 10.4049/Jimmunol.1201431 |
0.525 |
|
2011 |
Pilch-Cooper HA, Sieg SF, Hope TJ, Koons A, Escola JM, Offord R, Veazey RS, Mosier DE, Clagett B, Medvik K, Jadlowsky JK, Chance MR, Kiselar JG, Hoxie JA, Collman RG, et al. Circulating human CD4 and CD8 T cells do not have large intracellular pools of CCR5. Blood. 118: 1015-9. PMID 21068438 DOI: 10.1182/Blood-2010-05-282509 |
0.471 |
|
2011 |
Pilch-Cooper HA, Sieg SF, Hope TJ, Mercanti V, Offord R, Veazey RS, Mosier DE, Clagett B, Jadlowsky JK, Chance MR, Collman RG, Riddick NE, Hartley O, Lederman MM. Response: Absence of CCR5 intracellular pools in most CD4 and CD8 T cells Blood. 118: 1179. DOI: 10.1182/Blood-2011-05-350231 |
0.381 |
|
2008 |
Jadlowsky JK, Nojima M, Okamoto T, Fujinaga K. Dominant negative mutant cyclin T1 proteins that inhibit HIV transcription by forming a kinase inactive complex with Tat. The Journal of General Virology. 89: 2783-7. PMID 18931076 DOI: 10.1099/Vir.0.2008/002857-0 |
0.439 |
|
2008 |
Jadlowsky JK, Nojima M, Schulte A, Geyer M, Okamoto T, Fujinaga K. Dominant negative mutant cyclin T1 proteins inhibit HIV transcription by specifically degrading Tat. Retrovirology. 5: 63. PMID 18620576 DOI: 10.1186/1742-4690-5-63 |
0.46 |
|
2007 |
Funderburg N, Lederman MM, Feng Z, Drage MG, Jadlowsky J, Harding CV, Weinberg A, Sieg SF. Human -defensin-3 activates professional antigen-presenting cells via Toll-like receptors 1 and 2. Proceedings of the National Academy of Sciences of the United States of America. 104: 18631-5. PMID 18006661 DOI: 10.1073/Pnas.0702130104 |
0.319 |
|
Show low-probability matches. |